Scientists probe how lung cancer outsmarts key drugs
NCT ID NCT04222335
First seen May 03, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This study looks at why lung cancer cells stop responding to a class of drugs called EGFR inhibitors. Researchers will collect blood samples from 80 patients over time to track changes in tumor DNA and cells. The goal is to understand the early steps of drug resistance and find ways to prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Toulouse University Hospital
Toulouse, Occitanie, 31300, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could point toward new treatments that prevent or overcome drug resistance in lung cancer patients.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.